Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
DELSTRIGO (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
DELSTRIGO
Date registered
Evaluation commenced
Decision date
Approval time
192 working days (255)
Active ingredients
tenofovir disoproxil fumarate; lamivudine; doravirine
Registration type
EOI
Indication
New combination
DELSTRIGO is indicated for the treatment of HIV-1 infection in adults who are antiretroviral therapy (ART)-naïve with no known substitutions associated with resistance to doravirine, lamivudine, or tenofovir.